Table 1:

Genomic Abnormalities in Lung Cancer and Effective Targeted Therapy Options

Note.—ALK = anaplastic lymphoma kinase, BRAF = v-Raf murine sarcoma viral oncogene homolog B1, EGFR = epidermal growth factor receptor, FDA = Food and Drug Administration, NSCLC = non–small cell lung cancer, ORR = overall response rate, OS = overall survival, PD-1 = programmed death-1, PD-L1 = programmed death-ligand 1, PFS = progression-free survival, ROS-1 = ROS proto-oncogene 1, SCLC = small cell lung cancer.

^*The outcome data are based on trials of first-line erlotinib therapy for EGFR-mutant NSCLC.

^†Initially approved in 2003, which was before the discovery of EGFR mutations in NSCLC as a biomarker for the therapy, leading to low effectiveness in patients without EGFR mutations and resulting in retraction of FDA approval in 2005.

^‡The outcome data are based on a subcohort of patients with PD-L1 expression of ≥ 50% (40).

^§After progression on an appropriate FDA-approved targeted therapy in patients with tumors harboring EGFR or ALK gene abnormalities.